title: How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000494:pharmacology; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism*; D018572:Disease-Free Survival; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D000077157:Sorafenib; D000077210:Sunitinib; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D014408:Biomarkers, Tumor; D016207:Cytokines; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D000077210:Sunitinib